Evidence map›Paper›PMID 42325957›Full record

ArticleFrontiers in molecular neuroscience2026

Microbiota and mycobiota in chronic inflammatory demyelinating polyneuropathy: clinical and pathophysiological correlations.

Szymon Andrusiów, Anita Brzoza, Piotr Łacina, Marta Dratwa-Kuzmin, Justyna Raczkowska, Dorota Kujawa, Katarzyna Romańczuk, Marta Gancarek, Patrycja Bochen, Edyta Dziadkowiak and 4 more

Abstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Szymon AndrusiówDepartment of Neurology, Faculty of Medicine, University Centre of Neurology and Neurosurgery, Wrocław Medical University, Wrocław, Poland.
Anita BrzozaLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Piotr ŁacinaLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Marta Dratwa-KuzminLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Justyna RaczkowskaLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Dorota KujawaLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Katarzyna RomańczukLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Marta GancarekLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Patrycja BochenLaboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Edyta DziadkowiakDepartment of Neurology, Faculty of Medicine, University Centre of Neurology and Neurosurgery, Wrocław Medical University, Wrocław, Poland.
Bogumiła SzponarLaboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Łukasz ŁaczmańskiLaboratory of Genomics and Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Magdalena KoszewiczClinical Neurophysiology Laboratory, Faculty of Medicine, University Centre of Neurology and Neurosurgery, Wrocław Medical University, Wrocław, Poland.
Katarzyna Bogunia-KubikLaboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated neuropathy with incompletely defined triggers and no validated biomarkers. We investigated associations between bacterial and fungal communities, short chain fatty acids (SCFAs), and Methods: We enrolled 32 treatment naive CIDP patients and 15 healthy controls. Stool, serum and cerebrospinal fluid (CSF) samples were collected. Disability was assessed using the clinical scale and related to nerve conduction study (NCS) parameters. Results: CIDP was characterised by increased faecal bacterial alpha diversity and significant shifts in beta diversity relative to controls. Diversity patterns differed across clinical subgroups, including diabetes status and disability severity. Higher faecal bacterial diversity metrics correlated with greater NCS abnormalities, whereas associations with beta diversity measures were weaker. Taxonomic analyses identified enrichment of Discussion: We confirmed the increased gut microbiome alpha diversity in CIDP patients, as observed in previous research. Our findings suggest significant alterations in both gut microbiota and mycobiota during the course of CIDP, which correlate with clinical, electrophysiological, and laboratory parameters.

Indexed as

chronic inflammatory demyelinating polyneuropathy (CIDP)gut microbiotagut mycobiotaIL18 polymorphismsshort chain fatty acids (SCFAs)

Identifiers

PMID42325957
PMCPMC13276713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.